Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1084 of 6351
-
New drug shows promise in taming psoriatic arthritis flares
Disease control CompletedThe primary purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for young AML patients: epigenetic drugs plus chemotherapy show promise
Disease control CompletedThis is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
Phase 1 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Immunotherapy combo before chemo-radiation shows promise for esophageal cancer
Disease control OngoingAnti-PD-1 (nivolumab) or Anti-PD1/Anti LAG-3- (relaltimab) administration in the pre-operative setting with chemoradiation will be safe and feasible in patients with resectable distal esophageal/gastroesophageal junction cancer and will change cellular and molecular characteristi…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could a personal coach at home boost energy for cancer patients?
Symptom relief OngoingThis phase II-III study will be randomized (2:1) patients starting first-line oral targeted therapies (OTT) for metastatic cancer between an individualized supervised physical exercise programs (SPEP) by a personal coach, and recommended physical exercises via a booklet. Eligible…
Sponsor: UNICANCER • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo shows promise for advanced prostate cancer across races
Disease control CompletedThe primary goal is to prospectively estimate the median PFS of African American and Caucasian men with mCRPC taking apalutamide, abiraterone acetate, and prednisone. Secondary objectives include: PSA kinetics: to determine the duration of PSA response, time to nadir, and percent…
Phase 2 • Sponsor: Daniel George, MD • Aim: Disease control
Last updated Jun 26, 2026 16:33 UTC
-
Can an immune booster make radioiodine more effective against thyroid cancer?
Disease control OngoingThe purpose of this study is to find out what effects, good and/or bad, a drug called durvalumab combined with Thyrogen-stimulated RAI, has on the patient and thyroid cancer. Durvalumab is a drug that has been developed to activate the immune system by blocking a protein called p…
Early phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Bladder cancer study aims to keep tumors at bay with immunotherapy
Disease control OngoingThis is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder cancer.
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Engineered immune cells show promise against hard-to-treat leukemia
Disease control OngoingThis is a single-arm, open-label, single-center, phase I/II study to determine the safety and efficacy of CD19 CAR-T(ssCART-19) combined with autologous T cells engineered to express CD19, namely CD19+ feeding T cells (FTCs), as consolidation therapy in patients diagnosed with de…
Phase 1/2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Proton therapy offers new hope for head and neck cancer that returns
Disease control CompletedThe purpose of this study is to evaluate the tumor control and the side effects of using proton therapy for head and neck cancer that has come back.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug aims to help boys with duchenne walk longer
Disease control CompletedThis study is a long-term study of ataluren in participants with nonsense mutation Duchenne muscular dystrophy.
Phase 3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for Hard-to-Treat breast cancer? alisertib combo tested
Disease control CompletedThis phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell g…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for pancreatic cancer? immunotherapy cocktails tested in major trial
Disease control CompletedA Phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two c…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New hope for kids with sickle cell: stem cell transplant from mismatched blood type donors
Disease control Recruiting nowThe aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The non…
Phase 2 • Sponsor: University of Calgary • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New imaging technique could improve stent outcomes in heart patients
Disease control OngoingThe purpose is to compare median two-year clinical outcome after OCT guided vs. standard guided revascularization of patients requiring complex bifurcation stent implantation
Sponsor: Aarhus University Hospital Skejby • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New transplant approach shows promise for rare blood disorder
Disease control CompletedThis study is a prospective, multicenter phase II study with patients receiving haploidentical transplantation for Severe Aplastic Anemia (SAA). The primary objective is to assess overall survival (OS) at 1 year post-hematopoietic stem cell transplantation (HSCT).
Phase 2 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Microbubble 'Pops' could supercharge liver cancer radiation
Disease control CompletedThis phase II trial studies how well perflutren protein-type A microspheres and contrast-enhanced ultrasound work in improving response to radioembolization therapy in patients with liver cancer. Ultrasound contrast agents, such as perflutren protein-type A microspheres, use gas …
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Could a sleep apnea machine keep heart patients out of the hospital?
Disease control CancelledThe purpose of this study is to determine whether early diagnosis of obstructive sleep apnea and initiation of and adherence to CPAP therapy in hospitalized cardiac patients would impact 30-day hospital readmission rates.
Sponsor: Kaiser Permanente • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Ketamine during breast cancer surgery may stop chronic pain before it starts
Prevention CompletedAim 1: To determine the effectiveness of perioperatively administered ketamine to decrease acute and persistent postmastectomy pain (PPMP). Hypothesis 1.1: Patients undergoing partial or total mastectomy treated with a bolus and perioperative infusion of the NMDA-receptor antago…
Early phase 1 • Sponsor: Brigham and Women's Hospital • Aim: Prevention
Last updated Jul 22, 2026 00:00 UTC
-
New cocktail aims to keep myeloma at bay longer
Disease control OngoingThis study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
Phase 2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Jun 26, 2026 15:40 UTC
-
New combo therapy targets Hard-to-Treat liver and stomach cancers
Disease control Recruiting nowThis is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, adv…
Phase 2 • Sponsor: Teclison Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC